

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated Monday, March 18, 2019 (the “**Prospectus**”) issued by CanSino Biologics Inc. (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Hong Kong Public Offering and the International Offering described below before deciding whether or not to invest in the H Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any state securities laws of the United States.

The Offer Shares may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of securities of the Company in the United States.

## **CanSino Biologics Inc.**

## **康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

### **FULL EXERCISE OF OVER-ALLOTMENT OPTION**

#### **FULL EXERCISE OF OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option was fully exercised by the Joint Representatives (on behalf of the International Underwriters) on April 9, 2019 in respect of 4,450,400 additional H Shares (the “**Over-allotment Shares**”), representing approximately 7.8% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) to cover over-allocation under the International Offering. The Over-allotment Shares will be issued and allotted by the Company at HK\$22.00 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

A further announcement will be made by the Company after the end of the stabilization period.

#### **FULL EXERCISE OF OVER-ALLOTMENT OPTION**

The Company announces that the Over-allotment Option was fully exercised by the Joint Representatives (on behalf of the International Underwriters) on April 9, 2019 in respect of 4,450,400 Over-allotment Shares, representing approximately 7.8% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) to cover over-allocation under the International Offering. The Over-allotment Shares will be issued and allotted by the Company at HK\$22.00 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering. The Over-allotment Shares will be used to facilitate the delivery to the Cornerstone Investors who have agreed to a delayed delivery of Offer Shares subscribed by them.

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on April 12, 2019.

The shareholding structure of the Company immediately before and immediately after the allotment and issue by the Company of the Over-allotment Shares is as follows:

Shareholders	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of the Over-allotment Shares	
	Number of Shares	Approximately % of issued share capital	Number of Shares	Approximately % of issued share capital
Dr. Yu <sup>(1)</sup>	17,874,200	8.19%	17,874,200	8.03%
Dr. Zhu <sup>(1)</sup>	17,874,200	8.19%	17,874,200	8.03%
Dr. Qiu <sup>(1)</sup>	17,114,200	7.84%	17,114,200	7.69%
Dr. Mao <sup>(1)</sup>	16,334,200	7.49%	16,334,200	7.34%
LAV <sup>(2)</sup>	33,745,016	15.47%	33,745,016	15.16%
QM29 Limited	13,036,538	5.97%	13,036,538	5.86%
Future Industry Investment Fund (Limited Partnership)	8,855,336	4.06%	8,855,336	3.98%
Tianjin Qianyi Enterprise Management Partnership (Limited Partnership) <sup>(3)</sup>	3,474,600	1.59%	3,474,600	1.56%
Tianjin Qianrui Enterprise Management Partnership (Limited Partnership) <sup>(3)</sup>	3,299,475	1.51%	3,299,475	1.48%
Tianjin Qianzhi Enterprise Management Partnership (Limited Partnership) <sup>(3)</sup>	1,207,150	0.55%	1,207,150	0.54%
Other Shareholders <sup>(4)</sup>	31,703,184	14.53%	31,703,184	14.24%
Public Shareholders <sup>(5)</sup>	53,681,400	25.00%	58,131,800	26.11%
<b>Total</b>	<b>218,199,499</b>	<b>100%</b>	<b>222,649,899</b>	<b>100%</b>

*Notes:*

- (1) Dr. Yu, Dr. Zhu, Dr. Qiu and Dr. Mao are collectively interested in approximately 31.71% and will be collectively interested in approximately 31.08% of the total issued shares of the Company through the Concert Party Agreement immediately before and after the allotment and issue of the Over-allotment Shares, respectively.
- (2) LAV, through the equity interest held by LAV Spring, LAV Bio, Lilly Asia, LAV Amber Limited, Shanghai Li'an and Suzhou Litai in the Company, is entitled to control the exercise of 15.47% and will be entitled to control the exercise of 15.16% of the voting power at the general meeting of the Company immediately before and after the allotment and issue of the Over-allotment Shares, respectively.
- (3) Tianjin Qianyi, Tianjin Qianrui and Tianjin Qianzhi are consolidated by the Company when preparing the consolidated financial statements of the Company. Tianjin Qianyi, Tianjin Qianrui and Tianjin Qianzhi were established as the employee incentive platforms of the Company. Please refer to the Prospectus for details.
- (4) Other Shareholders include Shanghai Nuoqianjin, Jiaxing Huiguang, Mr. Jianfa Liu, Tianjin Heyue, Suzhou Huyanglin, Dachen Chuanglian, Shanghai Huiqiu, Ms. Xuan Liu, Qiming Rongxin, Jinshi Yikang, CITIC Investment, Gopher Yaoren, Gopher Hongben, Shanghai Licheng, Mr. Jianxi Du, Zhongxin Hengxiang and Qiming Rongchuang, all of whom are Independent Third Parties. Shares held by all of the aforesaid Shareholders are Domestic Shares and will not be counted towards public float.
- (5) The Shares held by the public Shareholders include 868,600 Shares held by Mr. Zhongqi Shao.

The additional net proceeds of approximately HK\$94.96 million, after deducting the underwriting fees, commissions and estimated expenses payable by the Company in connection with the exercise of the Over-allotment Option, from the issue of the Over-allotment Shares by the Company, will be used on a pro rata basis for the same purposes as set out in the section headed "Future Plans and Use of Proceeds – Use of Proceeds" in the Prospectus.

## **PUBLIC FLOAT**

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) and Rule 18A.07 of the Listing Rules that at least 25% of the Company's total issued share capital with a market capitalization of over HK\$375 million must at all times be held by the public.

A further announcement will be made by the Company at the end of the stabilization period in connection with the Global Offering pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

On behalf of the Board of Directors  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, April 9, 2019

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Dr. Zheng YIN as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive Directors.*